Investigational drug · Phase 2
QLH12016
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostatic Neoplasms, Advanced Prostate Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "QLH12016"
First trial start
2025
Oct 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QLH12016", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostatic Neoplasms
- Advanced Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "QLH12016" as an intervention, largest first.
Qilu Pharmaceutical Co., Ltd.Industry
NCT07198633 · 212 participants (planned) · Start Nov 5, 2025 · Primary completion Dec 2026
Drug: QLC5508; abiraterone acetate and 2 more · For: Advanced Prostate Cancer
Sites: Tianjin, China
Qilu Pharmaceutical Co., Ltd.Industry
NCT05973149 · 108 participants (planned) · Start Aug 31, 2023 · Primary completion Aug 31, 2025
Drug: QLH12016 · For: Prostate Cancer
Sites: Beijing, China; Nanjing, China
- Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate CancerNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07104110 · 50 participants (planned) · Start Oct 2025 · Primary completion Oct 2027
Drug: QLH12016; abiraterone acetate and 1 more · For: Prostatic Neoplasms
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Prostatic Neoplasms
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- 177Lu-PSMA-617Lutetium [177Lu] vipivotide tetraxetan, lutetium vipivotide tetraxetanPhase 33 trials
Novartis · Prostatic Neoplasms, Prostatic Neoplasm, Metastatic Castration Resistant Prostate Cancer (mCRPC)
- 64Cu-SAR-bisPSMAPhase 33 trials
Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
- ARDTPhase 32 trials
Novartis · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
- JNJ-101556143Phase 32 trials
Johnson & Johnson (Janssen) · Prostatic Neoplasms
- GV20-0251Phase 23 trials
GV20 Therapeutics · Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum
- DM002Phase 21 trial
Xadcera Biopharmaceutical (Suzhou) Co., Ltd. · Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.